STAT+: Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
Category: STAT+
STAT+: Biogen, FDA at odds over timing of crucial confirmatory trial of Alzheimer’s drug
Biogen and the Food and Drug Administration are at odds over the timing of a…
STAT+: Biogen isn’t worried about backlash to ‘bewildering’ price of Alzheimer’s drug
Amid a firestorm of controversy around its decision to charge $56,000 a year for an…
STAT+: Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate
WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly…
STAT+: Biogen’s big day is a Wall Street windfall for biotechs in Alzheimer’s
As Biogen soared Monday on the surprise Food and Drug Administration approval of its hotly…
STAT+: ‘The price is bewildering’:The price of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks
The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen…
STAT+: One Medical eyes the full lifespan with acquisition of Medicare-focused Iora Health
One Medical announced its plan on Monday to acquire Iora Health, expanding its primary care…
STAT+: Why Biogen may be sitting on the most lucrative product in pharmaceutical history
Biogen’s quest to win approval for a new Alzheimer’s disease treatment once seemed futile. Now…
STAT+: By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk
In order to approve a new Alzheimer’s treatment, the Food and Drug Administration is rewriting…
STAT+: Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Onduo’s new exec on Google’s data skills, real-world evidence, and moving the needle on outcomes
After leading the charge at Duke University to free health care data from its silos,…
STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells…
STAT+: EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’
Amid intense debate over equitable access to Covid-19 vaccines, the European Union is offering a…
STAT+: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?
Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells…
STAT+: Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Carbon Health dives into digital diabetes care with virtual clinic acquisition
As health care providers large and small prepare for a transition from virtual to in-person…
STAT+: Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’
Martin Shkreli’s drug company has a lot of problems. Revenue was cut in half last…
STAT+: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer
Merck said Thursday that giving its drug Keytruda immediately after surgery significantly reduced the risk…
STAT+: AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning
Lynparza, a cancer-fighting pill marketed by AstraZeneca and Merck, reduced the risk that breast cancer…
STAT+: After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug…
STAT+: Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval
A lymphoma drug that was approved later than expected by regulators is at the center…
STAT+: Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money
As personnel moves go, the hiring of Amy Abernethy by Verily is about as big…
.jpg)
STAT+: Pharmalittle: Purdue bankruptcy plan clears a major hurdle; Senate Finance chair probes AbbVie over taxes
Good morning, everyone, and how are you today? A spot of rain, and then some,…
STAT+: Senate finance chair investigates AbbVie over its corporate tax strategy
AbbVie, which is already being probed by congressional Democrats for its pricing practices, is now…
STAT+: The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price
When Amber Freed heard in 2020 that a drug might help save her young child…
STAT+: Pharmalittle: JAMA editor stepping down after podcast furor; global agencies urge $50 billion investment to fight Covid-19
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal
German drugmaker MorphoSys said Wednesday that it will acquire Constellation Pharmaceuticals for $1.7 billion to…
STAT+: How CVS is tapping into its consumer expertise in a new venture fund
CVS Health recently expanded its investing efforts with the launch of the CVS Venture Fund,…
STAT+: FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?
In response to Congressional concerns over prescription drug pricing, the Federal Trade Commission released a…
STAT+: Pharmalittle: Biden in no rush to allow drug imports from Canada; deal on Covid-19 IP waiver remains elusive
Hello, everyone, and nice to see you again after taking an extended weekend break. Nothing…
STAT+: A bootcamp for digital health executives seeks to demystify the inner-workings of the drug industry
Naomi Fried has watched the same plot unfold over and over again: A digital health…
.jpg)
STAT+: Amgen wins FDA approval for first KRAS-blocking lung cancer drug
The Food and Drug Administration on Friday approved the first drug that benefits patients with…
STAT+: Pharmalittle: How Pfizer’s Covid vaccine boxes complicated rollout; FDA and J&J near deal to reopen vaccine plant
Good morning! Elizabeth Cooney sitting in for Ed Silverman today as he gets an early…
Opinion: STAT+: SARS-CoV-2 brought the world to its knees. Its digital twin is helping bring us back
“Bad news wrapped up in protein.” That’s how the late Nobel Laureate Sir Peter Medawar…
STAT+: ‘We shouldn’t leave anybody behind’: Inequities in cancer genomics undercut promise of precision medicine
Translating the promise of cancer genomics into health equity has not yet become a reality,…
STAT+: Boxed in: How a single Pfizer decision disrupted the Covid vaccine rollout while boosting profits
Pfizer Covid-19 vaccines arrive in an insulated box, tightly packed with dry ice, roughly double…
STAT+: FDA revives a controversial program the Trump administration ended over ‘inaccuracies’
In an unexpected move, the Food and Drug Administration is reversing a decision by the…
STAT+: Pharmalittle: FDA authorizes another Covid-19 treatment; judge indicates Purdue reorganization plan can be voted on
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: From two unusual organ donations, scientists garner a unique trove of single-cell genetic data
Late at night, in a California hospital, a brain-dead patient was being prepared to offer…
STAT+: Drug makers argue an HHS rule would penalize them for offering co-pay coupons
After months of controversy, the pharmaceutical industry’s biggest trade group has filed a lawsuit accusing…
STAT+: Pharmalittle: Vaccine makers urge Biden to end support of Covid-19 IP waiver; Russia accused of sowing doubt over Pfizer shot
Rise and shine, everyone, the middle of the week is here. You made it this…
STAT+: In a possible sign of transparency, more leading universities are reporting clinical trial results
Over the past two years, many major U.S. universities have done a better job of…
STAT+: What deadline? Most clinical trials are still not reported on time to federal database
Amid ongoing calls for greater clinical trial transparency, a new analysis finds just 40% of…
STAT+: Pharmalittle: Moderna Covid-19 vaccine is effective in adolescents; U.S. lawmakers pitch a bill to create ‘biobonds’
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: ‘Underfunded and undervalued’: Ro’s acquisition of Modern Fertility puts a spotlight on health tech’s gender gap
After raising $500 million earlier this year — bringing its total funding up to $897…
STAT+: ‘It’s not a cure’: A gene therapy is opening a new chapter for children, but challenges endure
WEST BOYLSTON, Mass. — When Rachael and Pat Brown rattle off all that their daughter…
STAT+: Lawmakers pitch a bill to create $30 billion in ‘biobonds’ to jumpstart drug development
In a bid to jumpstart drug development, a bipartisan group of lawmakers introduced a bill…
STAT+: European regulatory body plans ‘joint action’ to bolster clinical trial reporting
The Heads of Medicines Agencies, an umbrella group for regulators in 30 European Union countries,…
STAT+: Pharmalittle: BARDA lacks cash to invest in new Covid-19 drug development; AstraZeneca CEO hits back at European Commission
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…